Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Rockwell Medical Announces Pricing of $17.5 Million Public Offering of Common Stock
-
Rockwell Medical Technologies (RMTI) Commences Public Offering of Common Stock
-
Rockwell Medical Announces Proposed Public Offering of Common Stock
-
Contura Announces Completion of Successful Refinancing Through $561.8 Million Term Loan Credit Facility
-
bluebird bio (BLUE) PT Raised to $124 at Cantor Fitzgerald
-
Amarin (AMRN) Vascepa RXs Outpace Industry as of 06/07 - Cantor Fitzgerald
-
Global Blood Therapeutics (GBT) PT Raised to $110 at Cantor Fitzgerald Amid HOPE Trial Results
-
Freddie Mac Announces Pricing of $477 Million Multifamily Small Balance Loan Securitization
-
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
-
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
-
Zoetis Inc. (ZTS) PT Raised to $130 at Cantor Fitzgerald
-
TherapeuticsMD (TXMD) PT Lowered to $13 at Cantor Fitzgerald
-
Teva Pharma (TEVA) PT Lowered to $9 at Cantor Fitzgerald
-
Perrigo Co. (PRGO) PT Lowered to $60 at Cantor Fitzgerald
-
Neos Therapeutics (NEOS) PT Lowered to $10 at Cantor Fitzgerald
-
Mylan (MYL) PT Lowered to $18 at Cantor Fitzgerald
-
Mallinckrodt plc (MNK) PT Lowered to $18 at Cantor Fitzgerald
-
Endo International plc (ENDP) PT Lowered to $4.75 at Cantor Fitzgerald
-
Cidara Therapeutics (CDTX) PT Lowered to $8 at Cantor Fitzgerald
-
Amneal Pharmaceuticals (AMRX) PT Lowered to $14 at Cantor Fitzgerald
-
Allergen (AGN) PT Lowered to $125 at Cantor Fitzgerald
-
Aclaris Therapeutis (ACRS) PT Lowered to $24 at Cantor Fitzgerald
-
CymaBay Therapeutic (CBAY) Selloff Overdone - Cantor
-
Oil tumbles on demand worries; stocks hit by trade, economic fears
-
Orchid Island Capital Announces June 2019 Monthly Dividend and May 31, 2019 RMBS Portfolio Characteristics
-
Haymaker Acquisition Corp. II Announces Closing of $400,000,000 Initial Public Offering, including Underwriters’ Over-Allotment Option of $50,000,000
-
Haymaker Acquisition Corp. II Announces Closing of $400,000,000 Initial Public Offering, including Underwriters’ Over-Allotment Option of $50,000,000
-
Cantor Sees 'Blockbuster Potential' In Aerie Pharma's (AERI) Rocklatan Script Data
-
Freddie Mac Prices $645 Million Multifamily K-Deal, K-LU1
-
Freddie Mac Prices $504 Million Multifamily K-Deal, K-C04
-
Alexco Announces Closing of US$6.5 Million Bought Deal Equity Financing
-
Haymaker Acquisition Corp. II (HYAC) Prices 35M Units IPO at $10/Unit
-
Haymaker Acquisition Corp. II Announces Pricing of $350,000,000 Initial Public Offering
-
Haymaker Acquisition Corp. II Announces Pricing of $350,000,000 Initial Public Offering
-
UPDATE: Hecla Mining (HL) PT Lowered to $1.75 at Cantor Fitzgerald
-
Health Insurance Innovations (HIIQ) PT Raised to $80 at Cantor Fitzgerald
-
Amicus Therapeutics (FOLD) PT Lowered to $19 at Cantor Fitzgerald
-
Mirati Therapeutics (MRTX) PT Raised to $85 at Cantor Fitzgerald
-
Alexco Resource (AXU) Announces $6.5 Million Bought Deal Equity Financing
-
Alexco Announces US$6.5 Million Bought Deal Equity Financing
-
Centene (CNC) Weakness 'Overdone' - Cantor Fitzgerald
-
AAC Announces Engagement of Cantor Fitzgerald & Co. to Lead Transaction Process
-
Mexico Worries 'De Minimis' for Bausch Health (BHC) - Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin (AMRN) Following Latest Vascepa Rxs
-
Cantor Fitzgerald Downgrades electroCore Inc. (ECOR) to Neutral
-
UPDATE: Cantor Fitzgerald Starts RTI Biologics (RTIX) at Overweight
-
UPDATE: Mereo BioPharma (MREO) Reports Positive Early 6 Month Data from Open Label Arm of Phase 2b Clinical Study of BPS-804 (setrusumab)
-
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the
-
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the
-
TIGERSHARES Announces Brand Change and Name Change for the TIGERSHARES China-U.S. Internet Titans ETF

